Business

ENA Respiratory has announced the closing of a $22.4 million Series B financing, including a previously announced $5 million investment from the Flu Lab and participation by the Gates Foundation. The proceeds will be used… Read more . . .

Viatris announced that it has acquired Aculys Pharma, which in 2022 had acquired development and commercialization rights to Neurelis’s NRL-1 (Valtoco) intranasal diazepam for the treatment of epilepsy in Japan, Australia, and other Asia-Pacific countries. In… Read more . . .

Chance Pharmaceuticals has announced a new agreement giving Huadong Medicine the rights to commercialize Chance Pharma’s CXG87 formoterol / budesonide DPI in mainland China. Financial details of the agreement were not disclosed. In March 2025,… Read more . . .

Lupin has announced that it will invest $250 million over 5 years to build a new 70,000 sq ft inhaler manufacturing facility in Coral Springs, Florida, USA, where the company opened an inhalation research center… Read more . . .

Italian biotech NanoPhoria Bioscience announced that it has raised €83.5 million in Series A financing to support development of its NP-MP1 “lung-to-heart nano-in-micro technology.” The company notes that the €83.5 million funding is the largest… Read more . . .

AeroRx Therapeutics announced that it has closed a $21 million Series A financing to support continued development of the company’s AERO-007 indacaterol / glycopyrrolate inhalation solution for the treatment of COPD. In 2022, AeroRx announced… Read more . . .

Leyden Laboratories announced that it has raised €30 million in equity financing from the European Innovation Council (EIC) Fund and Invest-NL to support development of its PanFlu intranasal human monoclonal antibody for the prevention and… Read more . . .

AstraZeneca has announced that it will sell the Airsupra albuterol / budesonide MDI directly to US patients through a web site called AstraZeneca Direct starting October 1, 2025. According to the company, patients with a… Read more . . .